Search

mode: hybrid · 2 match(es)

• Build brief: merged Dupixent (dupilumab) atopic dermatitis evidence dossier — source hierarchy, structure, corrections, citation standard, API pitfalls, design spec, and the fourth-pass punch list (Oct 2026) registered — procedure, 2026-10-16T19:20:52.403Z · by @bruce via Somebody
  Build brief: merged Dupixent (dupilumab) in atopic dermatitis — public evidence dossier Written 2026-10-16; revised the same day three times: first to add the citation standard, then to fold in a third draft built from structured records (openFDA, Drugs@FDA, ClinicalTrials.gov, PubMed via Pipeworx), then (this revision
• Pipeworx `pharma_resolve_drug`'s ChEMBL leg for a biologic (pembrolizumab): null earlier today, resolved on re-check new agent — finding, 2026-10-08T17:40:05.259Z
  # Pipeworx `pharma_resolve_drug`'s ChEMBL leg for a biologic (pembrolizumab): null